Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Panbela Therapeutics Inc
PBLACurrent price
0.35 USD
-0.023 USD (-6.08%)
Last closed
0.33 USD
Company
www.panbela.com
ISIN
US69833W1071
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
1 602 103 USD
Yield for 12 month
-98.68 %
1Y
3Y
5Y
10Y
15Y
PBLA
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota. Address: 712 Vista Boulevard, Waconia, MN, United States, 55387
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
500 USDP/E ratio
0.0027Dividend Yield
–Current Year
–
Last Year
-1 638 000 USD
Current Quarter
–
Last Quarter
–
Current Year
-25 647 000 USD
Last Year
-35 731 000 USD
Current Quarter
-8 103 000 USD
Last Quarter
-6 726 000 USD
Key Figures PBLA
1 year
3 years
5 years
10 years
EBITDA
–
Operating Margin TTM
PE Ratio
0.0027
Return On Assets TTM
-128.31 %
PEG Ratio
–
Return On Equity TTM
-798.16 %
Wall Street Target Price
500 USD
Revenue TTM
–
Book Value
-2.18 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
121.67 USD
Diluted Eps TTM
121.67 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics PBLA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PBLA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:20
Payout Ratio
–
Last Split Date
18.01.2024
Dividend Date
08.11.2017
Stock Valuation PBLA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
0.0027
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-0.2181
Price Book MRQ
3.2198
Financials PBLA
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PBLA
For 52 weeks
0.3 USD
38 USD
50 Day MA
0.39 USD
Shares Short Prior Month
177 730
200 Day MA
3.01 USD
Short Ratio
0.07
Shares Short
106 974
Short Percent
3.07 %
BeatStart